| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02633293 Details | 2022-12-02 Interventional | 2/3 | 243 | Treprostinil Emphysema Hypertension Hypertension, P… Lung Diseases Lung Diseases, … Pulmonary Fibro… Combined Pulmon… Interstitial Lu… Pulmonary Hyper… | Inhaled treprostinil became commercially available in the US following its approval for PH-ILD - | |||
| NCT02229149 Details | 2022-12-02 Interventional | 2 | 33 | Capecitabine Docetaxel Paclitaxel Pertuzumab Trastuzumab Vinorelbine Breast Neoplasm… Malignant Tumor… | per Sponsor request - | |||
| NCT00591318 Details | 2022-12-02 Interventional | 1/2 | 12 | Ceftriaxone Mental Disorder… Psychotic Disor… Schizophrenia Psychosis Schizoaffective… | Study was terminated after enrolling 12 patients due to poor enrollment rates - | |||
| NCT05633758 Details | 2022-12-01 Interventional | 2 | 0 | Metolazone Heart Failure Acute Decompens… | no participants enrolled - | |||
| NCT05260541 Details | 2022-12-01 Interventional | 2 | 11 | Pramoxine Mental Disorder… Stress Disorder… Stress Disorder… Trauma and Stre… Mental Disorder Post Traumatic … Post-traumatic … Stress Disorder | No longer developing for this indication - | |||
| NCT04866056 Details | 2022-12-01 Interventional | 1/2 | 1 | Azacitidine Myelodysplastic… Myeloproliferat… Neoplasms Preleukemia Primary Myelofi… Syndrome Myelofibrosis Myeloproliferat… | Corporate policy adjustments - | |||
| NCT04402723 Details | 2022-12-01 Interventional | 1 | 8 | Cytarabine Daunorubicin Leukemia, Myelo… Acute Myeloid L… | Corporate policy adjustments - | |||
| NCT04076761 Details | 2022-12-01 Interventional | 2 | 8 | Trifluridine Bile Duct Neopl… Cholangiocarcin… Bile Duct Cance… | Lack of Funding - | |||
| NCT05387642 Details | 2022-11-30 Interventional | 2 | 0 | Pramoxine Essential Tremo… Tremor | Sponsor no longer pursuing indication. - | |||
| NCT03848403 Details | 2022-11-30 Interventional | 1 | 70 | Ixekizumab Healthy | At the protocol-specified interim analysis, the sponsor decided to stop the trial. At protocol-specified interim analysis, the sponsor decided to stop trial. | |||
| NCT02414750 Details | 2022-11-30 Interventional | 2 | 78 | Vemurafenib Melanoma Metastatic Mela… | Slow accrual and changing treatment landscape - | |||
| NCT00858364 2007-005792-34 Details | 2022-11-30 Interventional | 3 | 2549 | Darbepoetin alf… Anemia Carcinoma, Non-… Lung Neoplasms Cancer Lung Cancer Non-Small Cell … | - - | |||
| NCT00823576 Details | 2022-11-29 Interventional | 4 | 60 | Ropivacaine Pain, Postopera… Postoperative P… | - - | |||
| NCT00436748 Details | 2022-11-29 Interventional | 3 | 116 | Darbepoetin alf… Anemia Kidney Diseases Renal Insuffici… Chronic Kidney … Kidney Disease | FDA and EMA agreed that the information that had been submitted to date was acceptable to meet
the requirements of the post-marketing commitment. - | |||
| NCT05456165 Details | 2022-11-25 Interventional | 2 | 1 | Atezolizumab Ipilimumab Colonic Neoplas… Colorectal Neop… Neoplasms | terminated due to reprioritization - | |||
| NCT03382925 Details | 2022-11-25 Interventional | 4 | 16 | Lidocaine Triamcinolone Triamcinolone A… Triamcinolone d… Triamcinolone h… Asthenia Radiculopathy Cervical Radicu… | Not enough cervical interlaminar patients who meet criteria in order to meet recruitment goals. Early termination leading to low enrollment which ended up being the greatest limitation. | |||
| NCT03011307 Details | 2022-11-23 Interventional | 2 | 126 | Oxytocin Pain, Postopera… Postoperative P… | Cessation of funding period prior to completion, due to slow recruitment during the pandemic. The trial was terminated early because of depletion of funding. Power analysis was based on 120 subjects and only 90 were studied before termination of funding . | |||
| NCT03854227 Details | 2022-11-22 Interventional | 1 | 54 | Docetaxel Neoplasms Advanced Solid … Metastatic Soli… | The study has been terminated based on a strategic evaluation within the current Pfizer
oncology portfolio. This decision is not due to any safety concerns or requests from any
regulatory authorities. - | |||
| NCT05481775 Details | 2022-11-21 Interventional | 2 | [14 Refs] | 0 | Immunomodulatin… Carcinoma, Non-… Lung Neoplasms Efficacy and Sa… Locally Advance… | Clincal decision based on previous results - | ||
| NCT04847440 Details | 2022-11-18 Interventional | 2 | 40 | Tenofovir Coinfection Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis D Herpesviridae I… Virus Diseases | Terminated by the Sponsor - |